Y-MABS THERAPEUTICS INC. - COMMON STOCK

Y-mAbs Reports Second Quarter 2025 Financial Results and Recent Corporate Developments

08 Aug 2025 03:35:00 By Nasdaq GlobeNewswire

Y-mAbs to Announce Second Quarter 2025 Financial and Operating Results on August 8, 2025

07 Aug 2025 04:30:00 By Nasdaq GlobeNewswire

SERB Pharmaceuticals Agrees to Acquire Y-mAbs Therapeutics

05 Aug 2025 05:30:00 By Nasdaq GlobeNewswire

Y-mAbs Hosts Virtual Radiopharmaceutical R&D Update Highlighting Clinical Progress and Expanded Pipeline

28 May 2025 03:35:00 By Nasdaq GlobeNewswire

Y-mAbs Presents GD2-SADA PRIT Trial in Progress Poster at the Advances in Neuroblastoma Research Meeting

26 May 2025 07:00:00 By Nasdaq GlobeNewswire

Y-mAbs to Host Virtual Radiopharmaceutical R&D Update on May 28, 2025

13 May 2025 04:05:00 By Nasdaq GlobeNewswire

Y-mAbs Reports First Quarter 2025 Financial Results and Recent Corporate Developments

13 May 2025 03:35:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Update to National Comprehensive Cancer Network® (NCCN®) Clinical Practice Guidelines in Oncology for Neuroblastoma to Include Naxitamab-gqgk (DANYELZA®)

07 May 2025 04:05:00 By Nasdaq GlobeNewswire

Y-mAbs to Announce First Quarter 2025 Financial and Operating Results on May 13, 2025

06 May 2025 04:05:00 By Nasdaq GlobeNewswire

Y-mAbs Presents Translational Pharmacokinetics of CD38-SADA from Pretargeted RIT Platform at 2025 American Association for Cancer Research (AACR) Annual Meeting

27 Apr 2025 12:00:00 By Nasdaq GlobeNewswire

Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating CD38-SADA Pre-targeted Radioimmunotherapy in Relapsed/Refractory Non-Hodgkin Lymphoma

25 Apr 2025 04:35:00 By Nasdaq GlobeNewswire

Y-mAbs Reports Fourth Quarter 2024 Financial Results and Recent Corporate Developments

04 Mar 2025 03:35:00 By Nasdaq GlobeNewswire

Y-mAbs Announces Publication of Phase 2 Interim Results in Nature Communications

03 Mar 2025 04:30:00 By Nasdaq GlobeNewswire

Y-mAbs to Announce Fourth Quarter and Full Year 2024 Financial and Operating Results on March 4, 2025

20 Feb 2025 13:05:00 By Nasdaq GlobeNewswire

Y-mAbs to Present at the Oppenheimer 35ᵗʰ Annual Life Sciences Conference

06 Feb 2025 04:30:00 By Nasdaq GlobeNewswire

Y-mAbs Presents Translational Pharmacokinetics of GD2-SADA from Pretargeted RIT Platform at the SNMMI Mid-Winter and ACNM Annual Meeting

31 Jan 2025 04:35:00 By Nasdaq GlobeNewswire

Correcting & Replacing – Y-mAbs Provides Strategic Business Update and 2025 Priorities

10 Jan 2025 06:26:05 By Nasdaq GlobeNewswire

Y-mAbs Appoints Experienced Commercial Leader as Head of DANYELZA Business Unit

10 Jan 2025 04:35:00 By Nasdaq GlobeNewswire

Y-mAbs Provides Strategic Business Update and 2025 Priorities

10 Jan 2025 04:05:00 By Nasdaq GlobeNewswire

Y-mAbs to Present at the 43rd Annual J.P. Morgan Healthcare Conference

23 Dec 2024 04:30:00 By Nasdaq GlobeNewswire